What Does China's Price Manipulation Ruling On Unilever Mean For Global Pharma? (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
[Editor's note: This is part two of a two-part feature; part one covered the background of China's National Development and Reform Commission charge against consumer goods company Unilever and what multinational companies operating in China should take away from the incident. This second part looks at the larger impact of China's inflation on pharma companies.]
You may also be interested in...
Unilever Growth Fueled By Personal Care, Emerging Markets
New launches in skin cleansing and hair care, and expansion to new geographies, drove Unilever’s personal-care division in the first fiscal quarter, the firm reports. The firm’s overall turnover reached €12.1 billion, up 11.9% versus the prior-year period.
Unilever Growth Fueled By Personal Care, Emerging Markets
New launches in skin cleansing and hair care, and expansion to new geographies, drove Unilever’s personal-care division in the first fiscal quarter, the firm reports. The firm’s overall turnover reached €12.1 billion, up 11.9% versus the prior-year period.
China's MOFCOM Promises Increased Scrutiny Over M&A In 2012
China Ministry of Commerce announcement of increased M&A scrutiny, sends companies scrambling to submit papers in fear of bureaucratic delays.